CRLBF (Cresco Labs) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRLBF Cresco Labs Inc CRLBF
29 GF Score
Price $0.74
GF Value $0.87
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Cresco Labs 5-Year EBITDA Growth Rate?

Cresco Labs CRLBF -5.46% 29 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates CRLBF with a GF Score™ of 29/100 and a GF Value™ of $0.87 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Cresco Labs's EBITDA per Share for the three months ended in Jun. 2026 was $0.06.

During the past 12 months, Cresco Labs's average EBITDA Per Share Growth Rate was -94.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cresco Labs was 46.90% per year. The lowest was -55.40% per year. And the median was 18.60% per year.

Cresco Labs  (OTCPK:CRLBF) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Cresco Labs 5-Year EBITDA Growth Rate Related Terms

CRLBF vs ZTS: 5-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cresco Labs 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Cresco Labs's 5-Year EBITDA Growth Rate falls into.


CRLBF
29GF Score
Cresco Labs Inc CRLBF
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cresco Labs 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Cresco Labs (CRLBF) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Cresco Labs and its competitors.
Is Cresco Labs' 5-Year EBITDA Growth Rate too high?
Cresco Labs' current 5-Year EBITDA Growth Rate is 0.00%. Overall, Cresco Labs has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cresco Labs' 5-Year EBITDA Growth Rate compare to ZTS?
Cresco Labs' 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Cresco Labs and its competitors. Cresco Labs's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cresco Labs stock overvalued right now?
Based on GuruFocus' analysis, Cresco Labs (CRLBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.87, compared to a current price of $0.74 — trading 14.8% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. Cresco Labs' overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cresco Labs (CRLBF), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cresco Labs (CRLBF) Overvalued in 2026?

Based on GuruFocus' analysis, Cresco Labs stock appears to be undervalued. The current stock price of $0.74 is trading 14.8% below its estimated GF Value™ of $0.87. GuruFocus considers Cresco Labs to be Modestly Undervalued.

Key valuation signals for CRLBF:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: $0.87 vs. price of $0.74 (14.8% below fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the CRLBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cresco Labs Business Description

Other Exchanges 6CQ:GermanyCL:Canada
Address 600 W. Fulton Street, Suite 800, Chicago, IL, USA, 60661
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture, and sell retail and medical cannabis products through Sunnyside, Cresco Lab's national dispensary brand, and others. The company operates in one segment: the cultivation, manufacturing, distribution, and sale of cannabis. The company's brand includes: Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's, and Remedi.
29GF Score

Get the complete analysis for CRLBF

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.74
Price
$0.87
GF Value